<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45038">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01667926</url>
  </required_header>
  <id_info>
    <org_study_id>2012-P-001042</org_study_id>
    <nct_id>NCT01667926</nct_id>
  </id_info>
  <brief_title>Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder</brief_title>
  <official_title>Randomized, Double-blind Ketamine Augmentation in Chronically Suicidal, Treatment-resistant Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ketamine infusions resulted in an acute reduction in global depression scores and in
      severity of suicidal ideation. The investigators therefore plan to investigate the
      feasibility and efficacy of repeated intravenous administration of ketamine in severely
      depressed, treatment resistant patients. The results of the study could lead to development
      of new strategies for treating depression.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale - 28 Items</measure>
    <time_frame>up to 4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects will be assessed with HAM-D</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systematic Assessment for Treatment Emergent Events (SAFTEE)</measure>
    <time_frame>up to 5 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjects will be monitored for emergence of side effects weekly for the first 8 weeks and then every two weeks for 8 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive 6 infusions of ketamine over three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive 6 infusions of normal saline over 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient with sever treatment resistant depression

          -  Currently depressed

          -  Currently under regular psychiatric care

          -  On an aggressive antidepressant regimen, stable for 4 weeks.

        Exclusion Criteria:

          -  No history of other major psychiatric illness, including bipolar

          -  No history of psychosis

          -  No history of drug abuse

          -  No major medical illness or unstable medical problem
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Cusin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Clinical and Reseach Program - MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>August 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Cristina Cusin, MD</investigator_full_name>
    <investigator_title>Instructor HSM</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
